Navigating the NSA Independent Dispute Resolution Process

The Evolving IDR Landscape: Challenges and Opportunities

Four years into the No Surprises Act, surprise bills for patients have been reduced successfully. But the Independent Dispute Resolution (IDR) system has led to payers and providers navigating competing interests, private equity-controlled middlemen ballooning costs, and patients ultimately paying higher premiums.

“Understanding the opposing side’s perspective is no longer optional – it’s essential for success,” explains Kim Bolton, CureIS compliance strategist and former health plan operations executive. “While payment disputes are unavoidable in our healthcare system, organizations that approach IDR strategically can collaborate with opposing parties to ensure fair financial outcomes, reduce administrative burden, and ultimately better serve the patients at the center of these disputes.”

Right now, that approach is the exception not the rule. IDR dispute submissions now exceed initial CMS projections by more than 100 times. Georgetown University’s Center on Health Insurance Reforms estimates that managing this system cost approximately $5 billion between 2022-2024, including $1.9 billion in administrative costs for payers and $656 million in IDR entity fees alone. Meanwhile, over 3 million disputes choked the system, prompting CMS to move aggressively to clear the backlog in 2025.

Paydirt for Providers – Pain for Payers – Pressure on Patients

The IDR process was designed to serve as the neutral arbiter for out-of-network payment disputes. However, arbitration fees can climb into the thousands per case, typically borne by the losing party. The Centers for Medicare & Medicaid Services (CMS) September 2025 fact sheet on backlog clearance signals a renewed push for efficiency, with additional certified IDR entities added to reduce the load.

CMS data also reveals a pattern: approximately 85% of resolved IDR cases result in provider victories, with payments typically three to four times the typical in-network qualifying payment amounts (QPAs), according to recent research.

Private equity-backed companies are key players in the costly IDR process, both as certified IDR entities that receive fees to arbitrate disputes and as third party middlemen extracting high payments from payers by – as a joint 2024 analysis by AHIP and the Blue Cross Blue Shield Association contends – “flooding” the IDR process with high volumes of ineligible submissions. Their report suggests up to 39% of claims submitted for IDR fail basic eligibility criteria, including:

• Services covered under Medicare/Medicaid rather than commercial insurance.
• Disputes previously resolved through other means.
• In-network claims incorrectly designated as out-of-network.
• Claims subject to state (not federal) surprise billing laws.

“This creates a compounding problem,” notes Bolton. “Contracted entities identify ineligible claims less than 50% of the time, and since they must refund payments for claims found to be ineligible, there’s little financial motivation for rigorous screening. This creates a perfect storm of misaligned incentives.”

The true cost lies in the operational chaos: payers incur massive costs disputing claims, while providers grapple with unclear QPAs and manual processes.

What Happens When the Worm Turns?

While providers are currently winning, “Payers are deploying specialized tools to push back,” observes Bolton. “And increased audits could expose providers to financial risk. In addition, arbitration fees are an enormous added cost.”

Failure Point #1. Eligibility: The Porous Front Door

The first crucial step in the IDR process is determining whether a claim is eligible. In 2024, 20 million qualifying claims were processed, and over 1.2 million were directed to IDR, many with incomplete or flawed data.

• For Payers: Over a quarter of ineligible submissions are filed outside the mandatory 30-business-day window, with many lacking essential service codes or patient identifiers.
• For Providers: Legitimate disputes are often rejected because payer-submitted QPAs are built on historically inaccurate or incomplete network data.

Without a single source of truth, teams waste cycles manually verifying information, increasing the risk of costly errors and compliance breaches and impacting patient trust in the system.

Failure Point #2. Timeline Management: The Unforgiving Clock

The IDR process operates on a timeline that applies strict calendar or business day deadlines, depending on the task. An open negotiation lasts 30 days; after that, IDR initiation must occur within a tight four-day window.

This unforgiving clock amplifies visibility gaps. Payers report receiving arbitration decisions before they are even aware a dispute has been filed. Providers, facing rushed data exchanges, are often forced into premature escalations.

Manual workflows exacerbate timeliness issues, causing missed deadlines, default decisions, and forfeited fees.

Failure Point #3. Strategic Negotiation: The Missed Off-Ramp

With an 85% provider win rate in IDR, there may be less overt incentive to engage in good-faith open negotiation. However, skipping this step is a missed opportunity to lower administrative burden and avoid arbitration fees, which can cost beyond $200 per party.

“Approaching open negotiation strategically means promptly requesting comprehensive data exchange, preparing evidence-based objections to QPA calculations, and knowing precisely when to conclude discussions if meaningful progress stalls,” says Bolton.

For providers, this requires preparing robust challenges supported by detailed service intensity documentation. For payers, it’s crucial to leverage advanced analytics to identify high-risk claims early and engage providers proactively before positions harden.

Ultimately, a shared data environment where both parties can align on market-based pricing is the most effective way to sidestep the adversarial nature of IDR altogether and contain costs while keeping the wellbeing of patients at heart.

Looking Ahead: The 2026 IDR Landscape

As we look ahead to 2026, healthcare organizations should prepare for significant system changes, including:

• Increased scrutiny of “batch” submissions.
• Heightened efforts to clear disputes within 30 days.
• Enhanced portal validations to prevent system misuse.
• Greater emphasis on real-time resubmissions.
• Potential new documentation requirements.

Additionally, as consumers face the impact of rising healthcare costs, driven in part by administrative inefficiencies, there’s growing pressure to streamline these processes.

“Organizations that thrive will implement three critical priorities,” advises Bolton. “First, standardized processing methodologies for consistent eligibility determination. Second, integrated technology solutions that eliminate data silos. And third, cross-functional collaboration that breaks down traditional barriers between financial, clinical, and administrative teams.”

The evolution of IDR from administrative function to strategic capability requires specialized expertise and purpose-built technology.

Technology Solutions, AI, and Automated Eligibility Verification

At CureIS, we’ve engineered solutions specifically designed to address the data challenges inherent in the IDR process. Our UniSync™ Health Data Management Platform+ (HDMP+) supports an intelligent eligibility verification engine that proactively prevents ineligible claims from entering the IDR pipeline.

UniSync™ consolidates unlimited data sources into a single validated repository, automatically identifying and correcting errors before they affect outcomes. Its intelligent automation capabilities provide:

1. Unified Data Foundations: A single source of truth that eliminates the fragmentation complicating eligibility verification.
2. Intelligent Process Automation: Advanced IDR workflows that instantly identify anomalies and trigger appropriate actions, eliminating hours of manual effort.
3. Integrated Compliance Frameworks: Purpose-built controls with comprehensive audit trails ensuring all deadlines and requirements are met.
4. Agentic AI for accelerated throughput, unlimited volume, and adaptability. CureIS solutions are fine-tuned to your policies and procedures, with agentic workflows automatically adapting to changes.

“Nimble data management and intelligent automation aren’t just nice-to-have capabilities,” says Bolton. “They’re essential components of financial sustainability in today’s healthcare environment and critical to success in your IDR strategy.”